Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q2 2024 Contract Research Organizations Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q2 2024 Contract Research Organizations Update

M&A activity within the Contract Research Organization (CRO) sector remained strong in Q2-2024, marked by nine strategic and three financial transactions. Industry leaders are expanding their geographical footprints, bolstering data capabilities, and building upon existing service offerings to fortify competitive positioning. Concurrently, private equity firms are actively investing in the sector, exemplified by Riverside’s recent platform investment in CRIO. Provident anticipates sustained PE interest, fueled by rising demand for services and a rapidly expanding R&D pipeline (6.6% CAGR 2014 – 2024 in drug count), alongside ample opportunities to capitalize on technological enhancements and realize returns.

Increasing drug development and trial costs are driving a continued reliance on the use of outsourced pharma services vendors. As competing CROs strive to provide the most efficient drug discovery and trial solutions, many are turning to M&A to realize operational leverage and tech enhancements.

To print and download the full Contract Research Organizations Update report, please click below…

[holo_button icon=”/wp-content/uploads/2024/07/Q2-2024-CRO-vF.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]